Viatris Inc. · NASDAQ:VTRS

Viatris — Merger or Acquisition (October 2023)

5 slides from Viatris's merger presentation, Oct 2, 2023

Slide 1: Divestitures Announcement
Divestitures Announcement October 1, 2023 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements”. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, Viatris announces agreements
Slide 3: Non-GAAP Measures
Non-GAAP Measures This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, 2022 e
Slide 4: Summary of Divestiture Transactions
($B) Previous Range (November 7, 2022) Total Estimated Transaction Value Estimated Retained Value Total Estimated Transaction and Retained Value Biosimilars (1) $3.335 $3.335 $3.335 Other Non-core Assets (1)(2) ~$5.0 - $6.0 ~$3.6 ~$1.6 ~$5.2 Total Pre-tax Proceeds ~$8.3 - $9.3 ~$6.94 ~$1.6 ~$8.5 Est
Slide 5: Divestiture Perimeter: OTC, API, Women's Healthcare, Non-Core Markets
OTC OTC products predominantly in European markets Includes 2 manufacturing sites, 1 R&D site, and potentially conveying headcount of ~700 Retained OTC switch candidates, such as Viagra® and Dymista®, and select OTC products in certain markets Would be expected to close in Q2 2024 API API business i